LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, announced today that management has commenced the preliminary due diligence and strategic planning process for the Company’s planned expansion into Colombia. The initial phase includes evaluating corporate, regulatory, legal, operational, and commercial requirements to establish a Colombian operating subsidiary and deploy its digital healthcare platform in the market.
The Company believes Colombia represents an attractive long-term opportunity as it advances its broader Latin American expansion strategy. The ongoing review process will assess corporate formation, regulatory compliance, healthcare technology implementation, strategic partnerships, local operational infrastructure, and other market entry considerations. This evaluation aims to build upon LataMed’s growing healthcare ecosystem by identifying opportunities to expand access to telehealth infrastructure, healthcare coordination technologies, digital healthcare services, insurance accessibility initiatives, pharmacy integration, payment accessibility solutions, and artificial intelligence-driven healthcare technologies in additional Latin American markets.
Management believes the continued expansion of digital healthcare infrastructure throughout Latin America presents significant opportunities to improve healthcare accessibility, strengthen patient engagement, and support technology-enabled healthcare delivery across underserved and developing markets. Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated: “Colombia represents an important strategic opportunity as we continue executing our long-term vision of building an integrated digital healthcare ecosystem across Latin America. While we remain in the early stages of evaluating market entry requirements, we believe it is important to establish the proper legal, operational, and strategic foundation before expanding into new jurisdictions. We are encouraged by the opportunities we see in Colombia and look forward to providing updates as the evaluation process progresses.”
The Company emphasized that the Colombia expansion initiative remains in the preliminary planning and due diligence stage. Management intends to complete the required corporate, regulatory, and operational review before proceeding with the establishment of a Colombian subsidiary and expects to provide additional updates as material developments occur. For additional information, please visit https://latamed.ai or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
